A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
The current price of AstraZeneca PLC in the market is ¥31,170.24, with a 24-hour trading volume of ¥12.27B. The asset's market cap is ¥48.44T, after moving 1.26% in the last day.
Tokenized AstraZeneca PLC is trading at ¥17,617.42, with a tokenized market cap of ¥9.97B and a 24-hour trading volume of ¥129.8M. The tokenized asset has moved 2.35% in the past 24 hours.